Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ii study of the Arbeitsgemeinschaft Internistische Onkologie
Lorenzen, S.; Schuster, T.; Porschen, R.; Al-Batran, S.-E.; Hofheinz, R.; Thuss-Patience, P.; Moehler, M.; Grabowski, P.; Arnold, D.; Greten, T.; Müller, L.; Röthling, N.; Peschel, C.; Langer, R.; Lordick, F.
Annals of Oncology Official Journal of the European Society for Medical Oncology 20(10): 1667-1673
ISSN/ISBN: 1569-8041 PMID: 19549707 DOI: 10.1093/annonc/mdp069
This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m(2), day 1, plus 5-FU 1000 mg/m(2), days 1-5 (CF), either alone or in combination with cetuximab (CET-CF; 400 mg/m(2) initial dose followed by 250 mg/m(2) weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Sixty-two eligible patients were included, 32 receiving CET-CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% versus 0%) and diarrhea (16% versus 0%). The overall response rate according to RECIST criteria was 19% and 13% and the disease control rate 75% and 57% for the CET-CF and CF arms, respectively. With a median follow-up of 21.5 months, the median progression-free survival was 5.9 and 3.6 months and median overall survival 9.5 and 5.5 months for CET-CF and CF, respectively. No KRAS codon 12/13 tumor mutations were identified in 37 evaluated samples. Cetuximab can be safely combined with CF chemotherapy and may increase the efficacy of standard CF chemotherapy.